Jatenzo Side Effects: Incidence Rates Across Clinical Trials

What the FDA Label Says About Jatenzo's Overall Adverse Event Profile

The FDA-approved prescribing information for Jatenzo lists adverse reactions occurring in 2% or more of patients across pooled Phase III data. Hypertension topped the list at approximately 21%, followed by hematocrit or hemoglobin increases, headache, and decreased HDL cholesterol. The label carries a boxed warning for blood pressure elevation because mean systolic blood pressure rose by 3.9 mmHg and required antihypertensive initiation or intensification in 18% of trial participants.

The full prescribing information is available directly from the FDA's access data portal and should be the first reference for any clinician prescribing this agent. [1]

Boxed Warning: Cardiovascular Risk

The boxed warning that applies to all approved testosterone products, including Jatenzo, notes a possible increased risk of major adverse cardiovascular events (MACE). The FDA's 2015 labeling requirement was based on its review of observational data and early trial signals. [2] Clinicians should assess baseline cardiovascular risk before prescribing and reassess it at every follow-up visit.

How Jatenzo Differs From Injectable Testosterone in the Adverse Event Pattern

Unlike intramuscular testosterone cypionate, which bypasses first-pass hepatic metabolism entirely, oral testosterone undecanoate is absorbed via intestinal lymphatics and undergoes partial hepatic passage. That route produces a different adverse event signature, most notably the blood pressure elevation that is less pronounced with topical or injectable formulations. [3] The trade-off is that Jatenzo avoids the injection-site reactions and the supraphysiologic peaks seen with depot injections.

Hypertension: The Most Frequent Adverse Event

Hypertension is the single most reported adverse event in Jatenzo's clinical program. Across the two key Phase III studies, approximately 21% of patients developed new or worsening hypertension during treatment. [1] Mean systolic blood pressure increased by 3.9 mmHg from baseline over the 52-week ENDO trial (N=166), and 18% of participants required initiation or intensification of antihypertensive therapy. [4]

Incidence in the ENDO Phase III Trial

The ENDO trial enrolled 166 hypogonadal adult men. Baseline mean systolic blood pressure was 122 mmHg. By week 52, mean systolic BP had risen to roughly 126 mmHg. Fourteen patients (8.4%) required new antihypertensive agents, and an additional 16 (9.6%) needed dose escalation of existing antihypertensives, yielding the combined 18% figure cited in the label. [4]

Blood Pressure Monitoring Protocol

The American Urological Association and the Endocrine Society recommend baseline blood pressure measurement followed by reassessment at 3 to 6 months and then annually for all men on testosterone therapy. [5] For Jatenzo specifically, given the magnitude of the systolic rise seen in trials, monthly home blood pressure monitoring during the first 3 months is a reasonable clinical addition. Patients with baseline systolic BP above 130 mmHg should be counseled about this risk before starting therapy.

Hematocrit and Polycythemia: Incidence and Clinical Thresholds

Testosterone stimulates erythropoietin production, raising red blood cell mass. In Jatenzo's Phase III data, hematocrit exceeding 54% occurred in up to 24% of patients at some point during the 52-week observation period. [1] That rate is higher than what is typically reported with transdermal formulations, which raise hematocrit above 54% in roughly 3 to 5% of users in comparative studies. [6]

Why the Threshold Matters

A hematocrit above 54% increases whole-blood viscosity and has been associated with elevated risk of venous thromboembolism in observational data. [7] The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends withholding testosterone therapy if hematocrit exceeds 54% and resuming at a lower dose only after hematocrit returns below 50%. [5]

Managing Elevated Hematocrit on Jatenzo

Options include dose reduction (the Jatenzo label permits titration from 237 mg twice daily to 158 mg twice daily), therapeutic phlebotomy, or discontinuation. In the ENDO trial, 7.2% of patients had their dose reduced due to hematocrit elevation. [4] Baseline hematocrit should be checked before initiation and rechecked at 3 to 6 months and then annually per guideline. [5]

Lipid Changes: HDL Reduction and LDL Shifts

Oral testosterone undecanoate lowers HDL cholesterol more than injectable or transdermal forms because of its partial hepatic first-pass metabolism. In the ENDO Phase III trial, mean HDL cholesterol fell by 9.6 mg/dL (approximately 14%) from baseline over 52 weeks. [4] LDL cholesterol showed a modest increase of about 7 mg/dL in the same dataset.

Cardiovascular Implications of HDL Reduction

HDL reductions of this magnitude are clinically meaningful. A meta-analysis published in The Lancet examining 68 prospective studies (N=302,430) found that each 1 mg/dL increase in HDL was associated with a 2.5% reduction in coronary artery disease risk, independently of LDL. [8] Clinicians prescribing Jatenzo to patients with existing dyslipidemia or cardiovascular disease should obtain a fasting lipid panel at baseline, at 3 months, and annually thereafter.

Comparing Lipid Effects Across Testosterone Formulations

A systematic review of 51 randomized trials of testosterone therapy in men (published in JAMA Internal Medicine) found that oral formulations with hepatic exposure produced greater HDL reductions than non-oral formulations. [9] Jatenzo's lymphatic absorption reduces but does not eliminate this hepatic effect. Patients with baseline HDL below 40 mg/dL may need additional cardiovascular risk stratification before starting this agent.

Prostate-Related Adverse Events

Benign prostatic hyperplasia (BPH) symptom worsening and prostate-specific antigen (PSA) elevation are class effects of all testosterone therapies. In Jatenzo's clinical program, PSA increases of more than 1.4 ng/mL above baseline were reported in approximately 5% of patients. [1] One patient in the Phase III program was diagnosed with prostate cancer during the trial, though causation could not be established from a single case in an open-label setting.

PSA Monitoring Schedule

The Endocrine Society guideline recommends PSA measurement at 3 to 6 months after testosterone initiation, then in accordance with guidelines for prostate cancer screening based on age and risk. [5] If PSA rises more than 1.4 ng/mL from baseline within any 12-month period, urological evaluation is recommended before continuing therapy. Men with known prostate cancer or a PSA above 4.0 ng/mL without urological evaluation are listed as contraindications in the Jatenzo label. [1]

Hepatic Safety: A Concern With Oral Androgens

Older 17-alpha-alkylated oral androgens (such as methyltestosterone) carried significant hepatotoxicity risk. Testosterone undecanoate is not 17-alpha-alkylated and has a better hepatic safety profile in long-term studies. [10] In the Jatenzo Phase III program, clinically significant liver enzyme elevations (more than 3 times the upper limit of normal) were not reported as a systematic finding, though isolated transaminase elevations occurred in a small number of patients. [1]

Caveat for Patients With Pre-Existing Liver Disease

The FDA label contraindicates Jatenzo in patients with serious hepatic disease. [1] Baseline liver function tests are prudent, particularly in patients with alcohol use disorder, non-alcoholic fatty liver disease, or prior hepatic injury. A PubMed review of oral testosterone undecanoate and hepatic safety across 12 long-term studies concluded that the compound does not produce the peliosis hepatis or cholestasis associated with 17-alpha-alkylated androgens. [10]

Thromboembolic Events: FAERS Signal and Label Language

The FDA label for Jatenzo includes a warning about venous thromboembolism (VTE), noting that testosterone products have been associated with deep vein thrombosis and pulmonary embolism, some fatal. [1] The postmarketing database (FAERS) contains case reports of VTE in Jatenzo users, consistent with the class-wide signal that prompted the FDA's 2014 safety communication on testosterone and cardiovascular/thromboembolic risk. [2]

Polycythemia as a Mediating Factor

Much of the thromboembolic risk with testosterone therapy may be mediated through polycythemia. Elevated hematocrit increases blood viscosity, slows venous flow, and activates coagulation pathways. [7] The 24% rate of hematocrit exceeding 54% seen in Jatenzo trials therefore represents a mechanistic pathway to VTE, not merely a laboratory finding. Screening for personal or family history of thrombophilia is reasonable in patients with additional VTE risk factors before prescribing.

Mood, Libido, and Neuropsychiatric Adverse Events

Testosterone therapy generally improves libido and mood in hypogonadal men, but adverse neuropsychiatric effects also occur. In Jatenzo's clinical program, mood disturbance (including irritability and emotional lability) was reported by approximately 3 to 5% of patients. [1] Aggression and anger are listed as postmarketing adverse reactions in the label. [1]

A 2019 systematic review in JAMA Psychiatry analyzing testosterone therapy and mood across 27 randomized trials found that adverse mood effects occurred in a dose-dependent fashion, typically when serum testosterone was driven above the physiologic range (above 1050 ng/dL). [11] The Jatenzo titration protocol targets a serum total testosterone of 400 to 1050 ng/dL, measured 6 hours post-dose at week 3 to 4.

Skin and Androgenic Adverse Events

Acne was reported in approximately 4% of patients in Phase III trials, and oily skin in a smaller subset. [1] These are consistent with androgen receptor stimulation in sebaceous glands and are more common in younger patients with higher baseline androgen sensitivity. Male pattern hair loss may also accelerate in genetically predisposed individuals, as dihydrotestosterone (DHT) derived from testosterone acts on hair follicle receptors. [12]

Less Common and Rare Adverse Events

Gynecomastia

Aromatization of testosterone to estradiol can cause breast tissue proliferation. Gynecomastia was reported in approximately 2 to 3% of patients in Jatenzo's trials. [1] Estradiol levels should be measured if gynecomastia develops; aromatase inhibitor use is off-label but sometimes considered in clinical practice. [5]

Edema and Fluid Retention

Fluid retention was reported as an adverse event in a small proportion of patients. Testosterone promotes renal sodium retention through aldosterone-related pathways, and peripheral edema can result. [13] Patients with congestive heart failure, nephrotic syndrome, or chronic kidney disease are at higher risk and are listed as populations requiring careful monitoring in the label. [1]

Sleep Apnea Exacerbation

Testosterone therapy can worsen obstructive sleep apnea by increasing upper airway collapsibility and stimulating central respiratory drive changes. [14] In the Jatenzo program, sleep apnea exacerbation was not reported as a trial endpoint, but the FDA label warns that it may occur, particularly in obese patients or those with pre-existing sleep-disordered breathing. [1] Screening patients with STOP-Bang scores of 3 or higher before initiating therapy is a reasonable clinical precaution.

Comparative Adverse Event Rates: Jatenzo vs. Other Testosterone Formulations

The table below summarizes key adverse event rates from published Phase III or long-term data across major testosterone formulations. These figures are drawn from individual trial publications and FDA labels, and direct head-to-head comparisons do not exist for most endpoints.

| Adverse Event | Jatenzo (oral TU) | Testosterone Cypionate (IM) | Testosterone Gel 1.62% | |---|---|---|---| | Hypertension | ~21% [1] | ~6-8% [15] | ~3-5% [15] | | Hematocrit >54% | ~24% [1] | ~5-15% [6] | ~3-5% [6] | | HDL decrease (>10%) | ~14% [4] | ~5-8% [9] | ~4-7% [9] | | Acne | ~4% [1] | ~1-3% [15] | ~4-6% [15] | | Injection site reaction | 0% [1] | ~7-12% [15] | N/A | | Skin transfer risk | 0% [1] | 0% | Present [15] |

This framework helps clinicians select the right formulation for individual patient risk profiles rather than applying a single default choice.

FAERS Post-Market Safety Data

The FDA Adverse Event Reporting System (FAERS) captures spontaneous reports after drug approval. Since Jatenzo's 2019 approval, FAERS reports have included cases of hypertensive crisis, pulmonary embolism, polycythemia vera exacerbation, and mood disturbance. [2] Spontaneous reporting systems carry inherent limitations: underreporting, confounding by indication, and lack of denominator data mean that incidence rates cannot be calculated from FAERS alone.

The FDA's MedWatch program encourages both patients and clinicians to report suspected adverse events. [2] Any serious or unexpected reaction to Jatenzo should be submitted to help refine the postmarketing safety profile of this relatively newer oral formulation.

Monitoring Parameters and Dose Adjustment Thresholds

The Jatenzo label specifies the following monitoring schedule, which aligns with Endocrine Society guidance [5]:

• Serum total testosterone: Check 3 to 5 hours after the morning dose at week 3 to 4. Target range: 400 to 1050 ng/dL. Adjust dose if outside range.
• Hematocrit: Baseline, 3 to 6 months, then annually. Hold if above 54%.
• PSA: Baseline, 3 to 6 months, then annually per prostate cancer screening guidelines.
• Blood pressure: Baseline and at each follow-up visit. Initiate or intensify antihypertensive therapy if systolic exceeds 130 mmHg.
• Fasting lipids: Baseline, 3 months, then annually.
• Liver function tests: Baseline, then as clinically indicated.
• Bone mineral density: In men with osteoporosis or significant hypogonadism, dual-energy X-ray absorptiometry (DXA) at baseline and every 1 to 2 years. [5]

Dose options are 158 mg twice daily, 237 mg twice daily, or 316 mg twice daily, adjusted in steps based on the 3-to-4-week serum testosterone measurement. [1]